Details of the Drug

General Information of Drug (ID: DM6OC53)

Drug Name
PDX-101
Synonyms
Belinostat; 414864-00-9; PXD101; PXD-101; Belinostat (PXD101); Beleodaq; 866323-14-0; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; PXD 101; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; UNII-F4H96P17NZ; Belinostat(Random Configuration); NSC726630; PX105684; PX 105684; F4H96P17NZ; CHEBI:61076; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PX-105684
Indication
Disease Entry ICD 11 Status REF
Plasma cell myeloma 2A83.1 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [1]
Primary cutaneous T-cell lymphoma N.A. Approved [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Haematological malignancy 2B33.Y Phase 1 [3]
Peripheral T-cell lymphoma 2A90.C Phase 1 [3]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01XH04: PDX-101
L01XH: Histone deacetylase (HDAC) inhibitors
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 318.3
Logarithm of the Partition Coefficient (xlogp) 1.7
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Clearance
The clearance of drug is 1240 mL/min []
Half-life
The concentration or amount of drug in body reduced by one-half in 1.1 hours [4]
Metabolism
The drug is metabolized via the hepatic UGT1A1 []
Unbound Fraction
The unbound fraction of drug in plasma is 0.06% [4]
Vd
The volume of distribution (Vd) of drug is 409 +/- 76.7 L []
Chemical Identifiers
Formula
C15H14N2O4S
IUPAC Name
(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Canonical SMILES
C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO
InChI
InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
InChIKey
NCNRHFGMJRPRSK-MDZDMXLPSA-N
Cross-matching ID
PubChem CID
6918638
ChEBI ID
CHEBI:61076
CAS Number
866323-14-0
UNII
F4H96P17NZ
DrugBank ID
DB05015
TTD ID
D0XT6W
VARIDT ID
DR00787
INTEDE ID
DR0184
ACDINA ID
D00866
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase (HDAC) TTBH0VX NOUNIPROTAC Modulator [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
UDP-glucuronosyltransferase 1A1 (UGT1A1)
Main DME 		DEYGVN4 UD11_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1,4-alpha-glucan-branching enzyme (GBE1) OTK2N05B GLGB_HUMAN Gene/Protein Processing [8]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (PLCE1) OTJISZOX PLCE1_HUMAN Gene/Protein Processing [8]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Gene/Protein Processing [9]
2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial (GCAT) OT6WZPWV KBL_HUMAN Gene/Protein Processing [8]
2-hydroxyacylsphingosine 1-beta-galactosyltransferase OT17ST61 CGT_HUMAN Gene/Protein Processing [9]
24-hydroxycholesterol 7-alpha-hydroxylase (CYP39A1) OTBAJT4I CP39A_HUMAN Gene/Protein Processing [8]
3',5'-cyclic-AMP phosphodiesterase 7B (PDE7B) OTK3SHT2 PDE7B_HUMAN Gene/Protein Processing [8]
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase 9 (FUT9) OTLIJBQY FUT9_HUMAN Gene/Protein Processing [8]
4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL) OTW7D1SV HPDL_HUMAN Gene/Protein Processing [9]
5-formyltetrahydrofolate cyclo-ligase (MTHFS) OTZ39JNR MTHFS_HUMAN Gene/Protein Processing [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1 0.3244 3.1148 0.2197 49.9719
ES5 GDSC1 -3.4321 -1.2869 -3.4328 89.9115
EW-18 GDSC1 -3.1014 -0.558 -3.1052 85.9457
ES7 GDSC1 -3.0016 -0.4546 -3.0058 85.1463
CHSA0108 GDSC1 -2.7313 0.3293 -2.7488 81.1367
CADO-ES1 GDSC1 -2.3156 -0.6224 -2.3158 81.4529
SK-N-MC CTRP2 -2.3067 -1.0145 -2.3067 55.636
ES8 GDSC1 -2.2382 2.7029 -2.4692 71.5807
U2OS GDSC1 -2.1669 0.1668 -2.1716 78.2727
EW-1 GDSC1 -2.1078 -0.2198 -2.1087 78.7755
TC-71 GDSC1 -1.9981 -0.3706 -1.9984 78.0903
EW-11 GDSC1 -1.7794 -0.2338 -1.7797 75.6962
ES1 GDSC1 -1.7151 0.0974 -1.7162 74.5564
MHH-ES-1 GDSC1 -1.5192 -0.1465 -1.5193 72.7719
EW-7 GDSC1 -1.498 0.8196 -1.5064 71.2306
EW-3 GDSC1 -1.3608 2.0415 -1.4378 67.6102
EW-13 GDSC1 -1.0757 5.2706 -1.8526 60.3448
EW-16 GDSC1 -0.9439 0.8035 -0.946 65.5213
SK-PN-DW GDSC1 -0.918 1.2264 -0.9271 64.8554
NOS-1 [Human HNSCC] GDSC1 -0.8346 2.6347 -0.9508 62.1791
SK-ES-1 GDSC1; CTRP2 -0.825 1.4048 -0.8274 45.7707
TC71 CTRP2 -0.2825 1.4435 -0.283 42.1524
A-673 GDSC1; CTRP2 -0.1229 2.1969 -0.129 41.1063
ES6 GDSC1 0.2356 5.0062 -0.3417 50.7843
SJSA-1 GDSC1 0.9238 4.9342 0.4299 44.0086
ES4 GDSC1 1.5652 10.8265 -1.4397 43.1736
HuO9 GDSC1 1.8123 3.8268 1.7006 32.0611
HOS GDSC1; CTRP2 1.8227 4.4715 1.7521 28.3633
SaOS-2 GDSC1; CTRP2 1.9029 2.9429 1.9027 27.592
EW-24 GDSC1 2.3661 5.419 1.8126 28.0269
NY GDSC1 2.4964 7.1487 1.2002 30.7461
HuO-3N1 GDSC1 2.5593 7.0536 1.3067 29.8586
H-EMC-SS GDSC1 3.3362 6.7827 2.1973 20.4814
G-292 clone A141B1 GDSC1; CTRP2 3.4079 7.6608 2.6074 20.4833
CAL-72 GDSC1 3.5276 5.4048 3.0306 13.4786
CHSA8926 GDSC1 3.5418 4.3605 3.4597 10.2934
CAL-78 GDSC1 3.9621 7.9359 2.207 17.7017
MG-63 GDSC1; CTRP2 4.0815 5.0189 4.073 13.1054
Hs 888.T CTRP2 4.4205 8.4172 3.3321 14.9707
CHSA0011 GDSC1 4.5533 9.5857 1.8803 17.6581
Hs 822.T CTRP2 6.1 7.7183 5.2533 3.2193
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 176 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 -1.7311 0.2128 -1.7313 51.8004
JM1 GDSC1; CTRP2 -3.56 -1.9618 -3.56 63.9831
Ku812 GDSC1 -5.7149 -3.8067 -5.715 99.0068
SU-DHL-16 GDSC1 -5.4009 -3.8645 -5.4009 99.2861
SU-DHL-10 GDSC1 -5.1002 -3.9032 -5.1002 99.517
WIL2 NS GDSC1 -4.4985 -2.4723 -4.4986 96.0339
SR GDSC1 -4.3139 -2.3575 -4.314 95.565
EoL-1 GDSC1; CTRP2 -4.1614 -1.2879 -4.1625 67.7777
SU-DHL-5 GDSC1 -4.0124 -2.4712 -4.0124 95.7655
MOLT-13 GDSC1 -3.9425 -1.6053 -3.9434 92.3397
VAL GDSC1 -3.7736 1.5166 -3.9349 80.7553
SU-DHL-8 GDSC1 -3.7708 -2.247 -3.7708 94.5516
YT GDSC1 -3.7617 -1.3096 -3.7633 90.8536
CA46 GDSC1; CTRP2 -3.6852 -1.0519 -3.6859 64.7253
SU-DHL-6 GDSC1 -3.6799 -2.3295 -3.6799 94.6864
ALL-PO GDSC1 -3.6468 -1.0425 -3.6497 89.5516
GA-10 CTRP2 -3.6184 -1.0143 -3.6191 64.2908
MY-M12 GDSC1 -3.6053 -1.7855 -3.6054 92.3599
Karpas-45 GDSC1 -3.5741 -2.1048 -3.5741 93.531
Loucy GDSC1 -3.416 -2.049 -3.416 92.8003
NU-DUL-1 GDSC1 -3.2702 -2.1553 -3.2702 92.5554
697 GDSC1; CTRP2 -3.2642 -1.7764 -3.2642 62.014
P30/OHK GDSC1 -3.2316 -1.6276 -3.2316 90.4647
VL51 GDSC1 -3.1508 -1.8116 -3.1508 90.7322
RPMI-8402 GDSC1 -3.126 -1.9691 -3.126 91.122
HuT 78 CTRP2 -3.1041 0.4527 -3.1154 60.7015
HEL GDSC1 -3.0687 -1.2393 -3.0689 88.297
KOPN-8 GDSC1 -3.0452 -1.4686 -3.0452 88.9824
QIMR-WIL GDSC1 -2.9766 -0.6545 -2.9787 85.7576
BCP-1 CTRP2 -2.9718 1.8103 -3.0398 59.4006
CCRF-CEM GDSC1 -2.937 -1.367 -2.9371 88.0272
MHH-PREB-1 GDSC1 -2.9145 -0.6701 -2.9162 85.5163
Karpas-620 GDSC1 -2.8668 -0.5024 -2.8695 84.6892
NALM-6 GDSC1 -2.8656 -1.364 -2.8656 87.5731
MOLP-8 GDSC1; CTRP2 -2.8642 -0.4691 -2.8649 59.3259
P12-Ichikawa GDSC1 -2.8485 -1.639 -2.8485 88.2533
Mino CTRP2 -2.8052 -1.1175 -2.8052 58.9556
MOLT-4 GDSC1 -2.7902 -1.2429 -2.7902 86.7055
ALL-SIL GDSC1 -2.7879 -1.3995 -2.7879 87.1454
HAL-01 GDSC1 -2.7745 -0.8852 -2.7749 85.4853
PF-382 GDSC1 -2.7737 -1.1769 -2.7738 86.3963
JSC-1 GDSC1 -2.7733 -0.8476 -2.7738 85.3559
BL-41 GDSC1; CTRP2 -2.7325 16.4127 -7.5106 53.434
MLMA GDSC1 -2.7231 -0.9798 -2.7233 85.4615
SET-2 CTRP2 -2.721 -1.046 -2.721 58.3948
RS4;11 GDSC1 -2.7122 -1.0976 -2.7123 85.7413
RPMI-8866 GDSC1 -2.6936 -0.7308 -2.6943 84.4957
CESS GDSC1 -2.6793 -1.4893 -2.6793 86.5215
BE-13 GDSC1 -2.6568 -1.3851 -2.6568 86.0903
Namalwa GDSC1; CTRP2 -2.655 -0.1418 -2.6561 57.9299
Daudi GDSC1; CTRP2 -2.6542 0.4494 -2.6602 57.8642
Pfeiffer CTRP2 -2.6521 0.0424 -2.6541 57.8965
Sc-1 GDSC1 -2.6372 -0.8576 -2.6375 84.5184
NB4 GDSC1 -2.6056 -1.0711 -2.6056 84.8921
OCI-Ly3 CTRP2 -2.5639 -0.6235 -2.564 57.3456
SU-DHL-4 GDSC1 -2.5565 -1.4734 -2.5565 85.3778
SUP-M2 GDSC1; CTRP2 -2.5457 0.1788 -2.5482 57.1904
ATN-1 GDSC1 -2.524 -1.3049 -2.524 84.7576
MC116 GDSC1 -2.5225 -1.973 -2.5225 85.5246
CTB-1 GDSC1 -2.5121 1.4725 -2.594 76.3656
P32/ISH GDSC1 -2.5027 -0.6613 -2.5032 83.0071
HuNS1 CTRP2 -2.4903 2.3445 -2.5794 56.4061
HC-1 GDSC1 -2.4798 -0.1302 -2.4835 81.2723
KE-37 GDSC1 -2.4701 -0.8027 -2.4703 83.1439
KMS-12-BM GDSC1 -2.4681 -1.2568 -2.4681 84.1481
MOLT-3 CTRP2 -2.4564 -0.2867 -2.4567 56.6256
AMO1 GDSC1 -2.4456 0.2728 -2.456 79.7984
DND-41 GDSC1; CTRP2 -2.4323 -0.6761 -2.4323 56.4716
Kasumi-1 CTRP2 -2.3987 -0.8668 -2.3987 56.2485
HH [Human lymphoma] GDSC1; CTRP2 -2.3719 0.7309 -2.3792 56.0071
A4/Fukuda GDSC1; CTRP2 -2.2971 0.3275 -2.2993 55.5495
ST486 GDSC1; CTRP2 -2.2889 -0.8359 -2.2889 55.5176
BL-70 CTRP2 -2.2559 -1.2837 -2.2559 55.2975
Karpas-299 GDSC1 -2.1849 -0.8046 -2.1849 80.6384
MN-60 GDSC1 -2.1685 5.7149 -3.1853 65.2972
GDM-1 GDSC1 -2.1528 0.9459 -2.1812 75.965
HT GDSC1 -2.1515 -0.1659 -2.1529 79.0128
BALL-1 GDSC1 -2.1422 -0.4375 -2.1426 79.5494
NKM-1 GDSC1 -2.1384 -0.337 -2.139 79.2996
KMS-11 GDSC1 -2.1162 -0.2904 -2.1169 79.0055
Reh GDSC1 -2.1153 -0.6979 -2.1154 79.7806
SUP-T1 GDSC1 -2.0872 -0.7191 -2.0872 79.5318
LC4-1 GDSC1 -2.0813 0.3083 -2.0873 77.2601
Ramos.2G6.4C10 GDSC1 -2.0577 -0.8411 -2.0577 79.3844
OCI-AML-2 GDSC1 -2.0537 0.0614 -2.0562 77.6689
OCI-Ly19 GDSC1; CTRP2 -2.0485 0.3101 -2.0496 53.9085
OPM-2 GDSC1; CTRP2 -2.0152 -0.7296 -2.0152 53.6943
DB GDSC1; CTRP2 -1.9876 -0.4955 -1.9876 53.51
THP-1 GDSC1 -1.9862 0.3578 -1.992 76.4037
SUP-B15 GDSC1; CTRP2 -1.9506 -0.3912 -1.9506 53.2635
TK [Human B-cell lymphoma] GDSC1 -1.9069 0.334 -1.9114 75.8209
M-07e CTRP2 -1.8907 -0.7989 -1.8907 52.8648
MOLM-13 GDSC1 -1.8702 0.9739 -1.8917 73.9592
MOTN-1 CTRP2 -1.8637 -0.4146 -1.8637 52.6849
ARH-77 GDSC1 -1.8554 -0.1951 -1.8558 76.4085
SIG-M5 GDSC1; CTRP2 -1.8415 -0.987 -1.8415 52.5368
RPMI-8226 GDSC1 -1.8241 0.1156 -1.8258 75.5614
NU-DHL-1 CTRP2 -1.8178 -0.732 -1.8178 52.3788
SEM CTRP2 -1.8115 -1.0969 -1.8115 52.3369
OCI-AML-5 GDSC1; CTRP2 -1.8058 -0.2535 -1.8058 52.299
SUP-HD1 GDSC1; CTRP2 -1.7953 1.3145 -1.8064 52.207
L-1236 GDSC1 -1.757 -0.3016 -1.7571 75.5439
TUR GDSC1 -1.7216 -0.7428 -1.7216 75.4752
JJN-3 GDSC1; CTRP2 -1.7153 1.0128 -1.7201 51.6881
HEL 92.1.7 CTRP2 -1.7088 -1.0683 -1.7088 51.653
Kasumi-2 CTRP2 -1.7081 -0.0776 -1.7082 51.6483
AML-193 CTRP2 -1.6892 -0.8831 -1.6892 51.5226
EJM GDSC1; CTRP2 -1.6805 0.663 -1.682 51.4617
BV-173 GDSC1 -1.671 -0.4454 -1.671 74.7234
A3/Kawakami GDSC1; CTRP2 -1.6513 -0.7614 -1.6513 51.2697
RL GDSC1; CTRP2 -1.6147 1.3869 -1.6247 51.0175
DEL GDSC1 -1.6136 0.5585 -1.6185 72.7814
JeKo-1 CTRP2 -1.6026 -0.541 -1.6026 50.9453
KG-1 GDSC1 -1.5827 -0.3357 -1.5827 73.6336
BC-1 GDSC1 -1.559 -0.2825 -1.559 73.3245
KMOE-2 GDSC1 -1.5525 0.0301 -1.553 72.9745
Hs 445 GDSC1 -1.5391 1.0234 -1.5543 71.1974
CMK CTRP2 -1.5304 -0.4205 -1.5304 50.4646
Raji GDSC1 -1.5229 2.2387 -1.6321 68.4044
Jiyoye GDSC1 -1.5057 0.1311 -1.5063 72.3582
LP-1 GDSC1; CTRP2 -1.5045 0.5705 -1.5052 50.2918
Farage GDSC1 -1.4995 -0.1502 -1.4996 72.5507
KO52 CTRP2 -1.4779 -0.0031 -1.4779 50.1144
BC-3 GDSC1 -1.4708 -0.3537 -1.4708 72.327
EB1 CTRP2 -1.4618 0.8997 -1.4638 50.0074
WSU-NHL GDSC1 -1.4336 0.5789 -1.437 71.018
EB2 GDSC1 -1.397 1.0357 -1.4096 69.9058
F-36P CTRP2 -1.3466 0.1071 -1.3466 49.2396
HL-60 GDSC1; CTRP2 -1.3343 -0.2824 -1.3343 49.1579
JVM-3 GDSC1 -1.3102 0.1695 -1.3105 70.1574
MV4-11 GDSC1 -1.3016 0.2828 -1.3022 69.9701
U266B1 GDSC1; CTRP2 -1.2826 0.1768 -1.2826 48.8133
ROS-50 GDSC1 -1.2283 2.9988 -1.4321 64.7507
KMS-20 CTRP2 -1.2132 1.6513 -1.2231 48.3614
KCL-22 GDSC1 -1.1759 0.6564 -1.1782 68.2312
RPMI-6666 GDSC1; CTRP2 -1.1641 1.4437 -1.1695 48.0309
OCI-AML-3 GDSC1; CTRP2 -1.147 0.0872 -1.147 47.9103
TF-1 CTRP2 -1.1034 -0.3313 -1.1034 47.6194
MOLT-16 GDSC1 -1.0703 0.2404 -1.0705 67.3104
L-363 GDSC1 -1.0618 0.6786 -1.0636 66.9502
OCI-Ly10 CTRP2 -1.0247 2.2085 -1.0486 47.1309
OCI-M1 GDSC1; CTRP2 -1.0199 -0.257 -1.0199 47.0636
ME1 GDSC1 -1.0097 0.6496 -1.011 66.3821
LAMA-84 GDSC1 -0.9774 0.4268 -0.9777 66.1278
GR-ST GDSC1 -0.9619 4.8302 -1.5909 60.1569
CTV-1 GDSC1 -0.9523 0.5362 -0.9529 65.7814
NOMO-1 GDSC1 -0.8065 1.8536 -0.8411 62.973
Mono-Mac-6 GDSC1 -0.7943 2.4908 -0.8889 62.0178
SCC-3 GDSC1 -0.6715 0.1942 -0.6715 62.415
KY821 GDSC1 -0.5777 0.216 -0.5777 61.2439
JURL-MK1 GDSC1 -0.5748 0.9989 -0.5764 61.1022
K-562 GDSC1; CTRP2 -0.5523 1.3597 -0.5532 43.9507
MEG-01 GDSC1 -0.4696 2.5376 -0.5498 58.8361
Karpas-422 GDSC1; CTRP2 -0.4551 2.6676 -0.4841 43.3739
Granta-519 GDSC1; CTRP2 -0.3373 3.2456 -0.4011 42.6758
ML-2 GDSC1 -0.2275 1.103 -0.2281 56.8464
Ci-1 CTRP2 -0.1701 1.709 -0.1712 41.4054
MJ CTRP2 -0.075 6.7131 -0.8278 42.3018
DG-75 GDSC1 0.0141 5.2038 -0.6467 52.6509
P31/FUJ GDSC1 0.1599 1.1323 0.1598 52.0254
L-428 GDSC1; CTRP2 0.2112 1.9016 0.2104 38.8641
PL-21 GDSC1 0.2452 4.4282 -0.1566 50.7501
Hs 611.T CTRP2 0.2509 4.2039 0.1126 38.9954
SU-DHL-1 GDSC1 0.4023 1.4083 0.4021 48.9957
EM-2 GDSC1 0.588 2.4952 0.5648 46.7412
RC-K8 GDSC1 0.9038 2.7974 0.8718 42.8757
SK-MM-2 GDSC1 1.0389 7.303 -0.358 44.5927
U-698-M GDSC1 1.3474 10.9213 -1.6958 44.5181
HD-MY-Z CTRP2 1.3597 3.1242 1.355 31.2257
JVM-2 GDSC1 1.8911 9.3281 -0.4129 39.7258
WSU-DLCL2 GDSC1 2.4408 11.1048 -0.7414 37.8394
HDLM-2 GDSC1 3.245 5.0916 2.8739 16.0322
Toledo CTRP2 4.9751 19.8441 -1.7656 29.5443
H9 GDSC1 6.5136 8.7257 3.5686 1.3512
L-540 GDSC1 6.6151 8.5631 3.6747 0.8042
KM-H2 GDSC1 7.2881 8.9195 3.8005 0.1693
⏷ Show the Full List of 176 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 -0.8358 3.2519 -0.9258 45.9846
KYSE-180 GDSC1 -1.2541 1.6575 -1.2929 67.4784
TE-15 GDSC1 -1.1414 4.021 -1.561 62.4418
TE-4 GDSC1 -0.5785 1.7301 -0.5981 60.7082
OE33 GDSC1; CTRP2 0.0273 2.5716 0.0146 40.1258
KYSE-270 GDSC1 0.4771 3.1617 0.3764 48.2018
KYSE-70 GDSC1 0.7451 3.0738 0.675 44.9534
OE21 GDSC1; CTRP2 0.8273 3.7137 0.7787 34.9154
TE-14 CTRP2 1.3145 3.4711 1.2987 31.5639
KYSE-410 GDSC1 1.3519 5.1145 0.8342 39.4989
TE-5 GDSC1; CTRP2 1.5403 4.9435 1.3798 30.5439
KYSE-150 GDSC1; CTRP2 1.6119 4.366 1.541 29.7676
KYSE-520 GDSC1; CTRP2 1.6538 5.373 1.418 30.0424
OE19 GDSC1; CTRP2 1.7669 2.8365 1.7668 28.4975
KYSE-450 GDSC1; CTRP2 2.1958 3.9479 2.1832 25.682
TE-11 GDSC1; CTRP2 2.284 4.0279 2.2702 25.0982
KYSE-510 GDSC1; CTRP2 2.4182 4.5977 2.3682 24.3266
KYSE-30 CTRP2 2.5239 4.8078 2.4559 23.6843
EC-GI-10 GDSC1; CTRP2 2.987 5.2673 2.8833 20.7229
TE-10 GDSC1 3.4615 12.2761 -0.3931 32.6071
T.T GDSC1 3.98 7.9711 2.2051 17.6436
TE-1 GDSC1 5.0638 7.6214 3.242 6.1678
KYSE-140 GDSC1 6.0394 8.3042 3.5144 2.2288
TE-9 GDSC1 6.3076 7.7034 3.8678 0.3412
TE-6 GDSC1 6.8086 8.4791 3.7807 0.3541
COLO 680N GDSC1 6.9471 8.6638 3.7669 0.3335
TE-8 GDSC1 7.3517 9.4241 3.6494 0.4653
⏷ Show the Full List of 27 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 1.6173 5.1852 1.4175 30.1641
MZ-PC-1 GDSC1 -1.8376 4.1339 -2.3497 66.3894
QGP-1 GDSC1 -0.7979 3.8997 -1.1561 60.1546
HuP-T4 GDSC1 -0.7869 1.6577 -0.8093 63.0033
SUIT-2 GDSC1 -0.5722 1.7192 -0.5911 60.6482
PaTu 8902 GDSC1 -0.4854 1.5133 -0.4946 59.8139
PSN1 GDSC1; CTRP2 -0.188 1.8621 -0.1903 41.5283
MIA PaCa-2 GDSC1; CTRP2 -0.125 2.3142 -0.1335 41.1272
BxPC-3 GDSC1 0.0528 1.955 0.0404 53.2975
HPAC GDSC1 0.1923 2.5073 0.1513 51.5493
KP-4 GDSC1 0.2824 2.4512 0.25 50.4772
DAN-G GDSC1; CTRP2 0.4799 1.75 0.4798 37.072
HuP-T3 GDSC1; CTRP2 0.6772 5.3486 0.3613 36.6971
AsPC-1 GDSC1; CTRP2 0.7954 4.5659 0.6414 35.4555
KP-3 GDSC1 0.8042 3.2659 0.7112 44.3106
Panc 03.27 GDSC1; CTRP2 0.8838 3.17 0.8693 34.4284
SU.86.86 GDSC1 1.5083 3.1724 1.4723 35.3877
Panc 04.03 GDSC1; CTRP2 1.6125 4.2131 1.5578 29.7093
Capan-1 GDSC1; CTRP2 1.6817 4.3329 1.6185 29.2768
Panc 10.05 GDSC1; CTRP2 1.7277 4.4459 1.6544 29.005
KP-2 GDSC1; CTRP2 1.7905 3.8483 1.7708 28.4058
Panc 08.13 GDSC1; CTRP2 1.8006 4.2068 1.7561 28.4224
PK-45H CTRP2 1.9145 4.7588 1.8121 27.86
Panc 02.03 GDSC1; CTRP2 2.1745 4.9995 2.0536 26.1926
SW1990 GDSC1; CTRP2 2.201 4.5711 2.1415 25.8062
PaTu 8988s CTRP2 2.226 4.3898 2.186 25.573
PL4 GDSC1 2.2593 5.9679 1.4774 30.6141
Hs 766T GDSC1; CTRP2 2.5175 6.2785 2.1289 24.8505
YAPC GDSC1 2.5582 6.3205 1.6355 28.0274
HPAF-II GDSC1 2.8201 8.2118 1.0177 29.9639
PaTu 8988t GDSC1; CTRP2 3.3368 6.6556 2.9025 19.5858
Capan-2 GDSC1; CTRP2 4.0589 8.734 2.8241 17.8983
CFPAC-1 GDSC1 6.1141 12.5032 1.6115 14.4606
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 3.6937 7.4017 2.612 14.1031
CHL-1 GDSC1 -2.6585 1.517 -2.7527 76.9135
VMRC-MELG GDSC1 -2.2783 -0.1351 -2.2805 79.9125
MZ-MEL-7 GDSC1 -1.9318 0.2311 -1.9352 76.2645
A-431 GDSC1 -1.9186 0.1101 -1.9207 76.4195
WM35 GDSC1 -1.5298 1.3837 -1.5615 70.3537
IPC-298 GDSC1 -1.4291 1.0752 -1.4437 70.1252
RPMI-7951 GDSC1 -1.395 0.6209 -1.3986 70.5694
Mel Ho GDSC1 -1.3657 1.5854 -1.4041 68.5759
G-361 GDSC1 -1.327 0.8448 -1.3335 69.5576
IGR-1 GDSC1; CTRP2 -1.2756 1.6302 -1.286 48.7754
A-375 GDSC1 -0.9959 0.8481 -0.9989 66.0705
IGR-37 GDSC1; CTRP2 -0.8922 1.6412 -0.8978 46.2243
IST-MEL1 GDSC1 -0.6124 1.6906 -0.6312 61.1121
Mel JuSo GDSC1 -0.5994 2.195 -0.6514 60.4919
WM1552C GDSC1 -0.5303 1.305 -0.5353 60.4462
LB373-MEL-D GDSC1 -0.4199 1.574 -0.4296 59.025
SK-MEL-30 GDSC1 -0.4112 3.0776 -0.5647 57.7599
WM88 CTRP2 -0.3473 3.637 -0.4511 42.8291
WM115 GDSC1; CTRP2 -0.08 1.551 -0.0803 40.8026
LOX-IMVI GDSC1; CTRP2 0.0049 1.9754 0.0028 40.2427
CP50-MEL-B GDSC1 0.0104 1.8131 0.0019 53.8339
HMV-II GDSC1 0.073 2.6559 0.0113 52.9096
UACC-257 GDSC1; CTRP2 0.1555 3.5614 0.0876 39.4324
SK-MEL-24 GDSC1; CTRP2 0.2352 2.3218 0.231 38.7153
COLO 792 GDSC1; CTRP2 0.2606 5.3623 -0.0953 39.4751
SK-MEL-3 GDSC1; CTRP2 0.3147 2.7358 0.3026 38.2106
A101D GDSC1; CTRP2 0.4775 1.7202 0.4775 37.0874
451Lu GDSC1 0.5091 2.5656 0.4778 47.7254
MeWo GDSC1; CTRP2 0.5243 2.7205 0.5164 36.8014
MMAc-SF GDSC1 0.5699 2.593 0.5392 46.9801
HT-144 GDSC1; CTRP2 0.572 3.2519 0.5449 36.5455
WM793 GDSC1 0.5789 1.9809 0.5753 46.8008
GAK GDSC1 0.6245 1.7247 0.6239 46.2204
WM266-4 CTRP2 0.6783 3.241 0.6551 35.8254
COLO 829 GDSC1; CTRP2 0.7266 4.1799 0.6234 35.7554
LB2518-MEL GDSC1 0.8436 3.5713 0.7014 43.9919
M14 GDSC1 1.0093 4.0889 0.7676 42.3759
SK-MEL-1 GDSC1 1.0616 3.7268 0.9069 41.4505
WM983B CTRP2 1.1868 5.7927 0.8097 33.5651
SK-MEL-2 GDSC1; CTRP2 1.2447 3.0544 1.2399 31.9924
UACC-62 GDSC1; CTRP2 1.2565 2.3398 1.2564 31.898
K029AX CTRP2 1.3147 3.7409 1.2847 31.6098
COLO 679 GDSC1 1.3748 6.3439 0.3934 40.7574
Malme-3M CTRP2 1.3784 6.5829 0.7957 32.9467
COLO 800 GDSC1; CTRP2 1.472 5.2966 1.2369 31.2427
SK-MEL-28 GDSC1 1.5355 3.1995 1.4982 35.0572
HMCB CTRP2 1.5721 4.8352 1.4327 30.2622
MZ-MEL-2 GDSC1 1.5855 3.2569 1.5449 34.453
RVH-421 GDSC1; CTRP2 1.6073 5.5851 1.3193 30.523
A-388 GDSC1 1.6534 3.8707 1.5193 34.1588
CP66-MEL GDSC1 1.6896 2.7416 1.6857 32.929
COLO 783 GDSC1 1.9642 4.2381 1.7713 30.678
A2058 GDSC1; CTRP2 1.9901 2.9782 1.99 27.0107
CJM [Human melanoma] CTRP2 2.0676 3.1998 2.0671 26.4958
WT2-iPS GDSC1; CTRP2 2.1182 6.456 1.6405 27.7963
Hs 294T CTRP2 2.2432 3.5258 2.2414 25.3302
Hs 938.T GDSC1 2.2985 4.3754 2.0988 26.5854
SK-MEL-5 GDSC1 2.3985 10.0001 -0.2449 36.7583
SH-4 GDSC1 2.4204 8.2339 0.6201 33.7543
G-mel GDSC1 2.5789 8.7754 0.5163 33.3464
Hs 895.T CTRP2 2.8163 6.518 2.3817 23.0367
Hs 940.T GDSC1; CTRP2 2.8328 6.4545 2.4194 22.8507
WM278 GDSC1 6.478 9.2924 3.3203 2.7224
DJM-1 GDSC1 7.0661 8.9056 3.726 0.3873
Hs 934.T CTRP2 7.2317 11.7132 4.1282 6.0264
Hs 688(A).T CTRP2 7.3216 11.0755 4.4971 4.4114
Hs 839.T CTRP2 7.491 12.582 3.8886 6.6082
EquiPSC Line K2 GDSC1 2.348 6.0215 1.5475 29.7091
⏷ Show the Full List of 69 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OACP4 C GDSC1 -2.7015 -0.964 -2.7017 85.2708
ESO-26 GDSC1 -1.0948 0.4573 -1.0955 67.4887
OACM5.1 C GDSC1 -0.9605 1.9725 -1.0105 64.2981
KYAE-1 GDSC1 -0.8353 0.9854 -0.8386 64.1565
KYSE-50 GDSC1 -0.6347 1.2935 -0.6409 61.6597
ESO-51 GDSC1 -0.5294 2.5137 -0.6104 59.4592
SK-GT-4 GDSC1 -0.3208 2.2433 -0.3637 57.5052
FLO-1 GDSC1 0.344 2.1907 0.3294 49.7286
KYSE-220 GDSC1 0.6688 2.3345 0.6566 45.7099
HCE-4 GDSC1 7.4349 15.9751 0.8407 15.3082
TE-12 GDSC1 8.0196 11.0516 3.3189 1.1407
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; CTRP2 0.9242 5.1323 0.6766 34.8902
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IMR-32 CTRP2 -4.3962 0.5826 -4.441 67.8201
SJNB-12 GDSC1 -3.3661 2.6126 -3.671 76.3772
CHP-212 GDSC1; CTRP2 -2.9537 -0.9301 -2.9538 59.9378
SJNB-13 GDSC1 -2.895 -1.1768 -2.8951 87.1539
KP-N-YS GDSC1 -2.6861 3.1722 -3.0456 72.4487
MHH-NB-11 GDSC1 -2.6206 0.5958 -2.6459 79.6977
SK-N-DZ GDSC1; CTRP2 -2.498 1.4927 -2.5306 56.6807
NH-12 GDSC1 -2.3653 1.365 -2.4302 75.9466
Kelly GDSC1 -2.3084 -0.4861 -2.3089 81.0638
SJNB-6 GDSC1 -2.2935 -1.1631 -2.2935 82.2708
TGW GDSC1 -2.1278 -0.4025 -2.1282 79.3482
NH-6 CTRP2 -2.0907 1.0547 -2.1004 54.1517
CHP-134 GDSC1 -1.8945 -0.0114 -1.8957 76.4531
GI-ME-N GDSC1 -1.7 1.9889 -1.7905 70.2152
NB(TU)1 GDSC1 -1.5894 0.4273 -1.5924 72.7882
IMR-5 GDSC1 -1.4619 2.5464 -1.609 67.3097
SK-N-SH GDSC1; CTRP2 -1.3223 1.7901 -1.3378 49.0869
SK-N-MC-IXC GDSC1 -1.1704 0.902 -1.1759 67.8903
NB69 GDSC1 -1.0896 0.1949 -1.0897 67.5582
SJNB-7 GDSC1 -0.9943 1.5119 -1.0157 65.2918
SK-N-AS GDSC1; CTRP2 -0.8772 3.4948 -0.9963 46.2896
SJNB-14 GDSC1 -0.145 0.3806 -0.145 55.8367
SJNB-10 GDSC1 -0.0407 2.2038 -0.0689 54.3523
SK-N-FI GDSC1; CTRP2 0.1556 2.9662 0.1302 39.3101
GOTO GDSC1 0.1749 4.1497 -0.158 51.4743
SK-N-BE(2)-M17 GDSC1 0.4981 4.4021 0.1267 48.2176
SK-N-BE(2) CTRP2 0.6146 3.8762 0.54 36.41
SiMa GDSC1 0.9628 12.5228 -2.8298 47.0965
CHP-126 GDSC1 2.2659 10.6383 -0.6791 38.4926
SJNB-5 GDSC1 2.4607 9.2847 0.1588 35.222
LA-N-6 GDSC1 3.1971 9.2781 0.8537 28.9478
NB1 GDSC1 4.542 12.0235 0.6529 24.5028
SJNB-17 GDSC1 5.2458 14.9 -0.2182 25.8271
KP-N-YN GDSC1; CTRP2 7.523 16.7779 1.8545 14.4014
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC1 -0.0975 2.8113 -0.1883 54.7484
SNU-869 CTRP2 1.2397 5.4341 0.954 32.9364
Cancer Drug Sensitivity Data Curated from 86 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDA-MB-453 GDSC1; CTRP2 -1.9114 -0.8636 -1.9114 53.0026
HCC1599 GDSC1 -1.7213 -0.977 -1.7213 75.5273
Evsa-T GDSC1 -1.696 -0.5179 -1.696 75.0603
OCUB-M GDSC1 -1.6081 -0.3539 -1.6081 73.9379
CAL-148 GDSC1 -1.5803 -0.4379 -1.5803 73.6635
DU4475 GDSC1; CTRP2 -1.2903 0.833 -1.2913 48.8658
HCC70 GDSC1 -1.0498 3.6661 -1.3752 62.3447
T-47D GDSC1; CTRP2 -0.985 1.5484 -0.9902 46.8407
HCC1428 GDSC1; CTRP2 -0.6751 1.0909 -0.6754 44.767
MDA-MB-361 GDSC1; CTRP2 -0.5904 1.1623 -0.5908 44.2031
AU565 GDSC1; CTRP2 -0.5112 1.8221 -0.5156 43.6867
MDA-MB-330 GDSC1 -0.3508 1.8169 -0.368 58.1011
SK-BR-3 CTRP2 -0.1044 1.9988 -0.1075 40.9739
MFM-223 GDSC1 -0.0794 2.0143 -0.098 54.8634
CAMA-1 GDSC1 -0.0399 4.5478 -0.5018 53.3584
HCC1806 GDSC1 -0.0072 2.459 -0.0536 53.8839
EFM-19 GDSC1 0.0085 7.235 -1.4091 52.1255
MDA-MB-231 GDSC1 0.0407 9.1951 -2.2085 51.5684
EFM-192A GDSC1; CTRP2 0.048 4.5334 -0.1577 40.4877
HCC1569 GDSC1 0.1213 3.6341 -0.0945 52.1276
HCC202 GDSC1; CTRP2 0.1306 3.6502 0.0527 39.6248
HCC38 GDSC1; CTRP2 0.1713 2.4703 0.1637 39.1519
COLO 824 GDSC1 0.183 2.8848 0.1009 51.6066
HCC1500 GDSC1; CTRP2 0.2268 2.497 0.2194 38.7815
CAL-85-1 GDSC1; CTRP2 0.4467 4.7241 0.2387 37.9016
CAL-120 GDSC1 0.6126 6.0848 -0.3145 47.5826
MDA-MB-157 GDSC1; CTRP2 0.7122 3.3867 0.6821 35.6216
ZR-75-30 GDSC1; CTRP2 0.7314 5.2692 0.438 36.2827
HCC1937 GDSC1 0.7314 2.5273 0.7114 44.961
BT-474 GDSC1; CTRP2 0.7762 3.7194 0.7247 35.2646
HCC2218 GDSC1; CTRP2 0.8502 3.0413 0.8394 34.6402
UACC-812 GDSC1 0.8674 3.7658 0.6879 43.8237
HDQ-P1 GDSC1 0.9232 5.5026 0.2345 44.425
HCC2157 GDSC1 1.0289 5.1756 0.4635 43.0889
HCC1419 GDSC1; CTRP2 1.0483 3.3381 1.0312 33.3416
MDA-MB-415 GDSC1; CTRP2 1.3663 3.0188 1.3633 31.1761
JIMT-1 GDSC1 1.6176 5.6094 0.9409 37.2264
MDA-MB-175-VII GDSC1 1.679 4.3991 1.4162 34.5631
BT-20 GDSC1; CTRP2 1.7227 4.7103 1.6139 29.158
Hs 578T GDSC1; CTRP2 1.7286 4.1936 1.6817 28.9096
UACC-893 GDSC1 1.8696 6.9832 0.6384 36.7889
MRK-nu-1 GDSC1 1.9815 8.8114 -0.0816 38.42
BT-549 GDSC1; CTRP2 2.0074 4.3435 1.9607 27.0521
MDA-MB-468 GDSC1; CTRP2 2.2496 5.0925 2.1187 25.7273
YMB-1-E GDSC1 2.3483 7.3891 0.9419 32.785
MDA-MB-436 GDSC1 2.5998 7.1645 1.2961 29.6977
HCC1187 GDSC1 2.9564 6.8266 1.8063 24.9072
HCC1395 GDSC1 3.6091 8.5157 1.6049 23.1092
HCC1954 GDSC1 4.163 9.1873 1.7555 19.9114
CAL-51 GDSC1 4.5588 8.4866 2.4335 13.8356
MCF-7 GDSC1 4.8549 9.0051 2.4084 13.0119
Hs 578Bst CTRP2 5.0394 8.0356 4.1238 10.2478
BT-483 GDSC1 6.6405 13.069 1.697 12.5977
BT 416 CTRP2 -0.0192 2.2185 -0.0245 40.4134
BT 145 CTRP2 0.0404 3.8119 -0.0604 40.2801
BT164 CTRP2 0.96 5.0475 0.7326 34.5938
BT 428 CTRP2 1.1767 5.508 0.8684 33.4198
BT 179 CTRP2 1.2735 4.1699 1.2047 32.0128
BT 245 CTRP2 1.2776 3.8319 1.2397 31.8834
BT 112 CTRP2 1.4338 7.4219 0.579 33.3909
BT 224 CTRP2 1.5008 4.5206 1.4036 30.5951
BT 139 CTRP2 2.2075 5.3117 2.032 26.1614
BT 216 CTRP2 2.3093 4.5092 2.2624 25.0418
BT 131 CTRP2 2.5001 5.5002 2.3102 24.2652
BT 330 CTRP2 2.881 6.9933 2.2932 23.1638
BT 239 CTRP2 3.0756 9.7841 1.3559 25.9127
BT 333 CTRP2 3.1441 5.9949 2.8926 20.1996
BT 159 CTRP2 3.1472 6.6675 2.6929 20.9161
BT 228 CTRP2 3.1912 7.1559 2.5694 21.243
BT 504 CTRP2 3.5439 7.1924 2.9343 18.8687
BT 172 CTRP2 3.5761 7.3652 2.9024 18.8983
BT 248 CTRP2 3.8586 8.1046 2.8963 18.1458
BT 231 CTRP2 4.211 11.0681 1.8786 21.1003
BT 359 CTRP2 4.4417 8.5051 3.3133 14.9924
BT147 CTRP2 4.5627 8.3684 3.497 13.9544
BT 320 CTRP2 4.7187 6.7119 4.373 10.0925
BT 232 CTRP2 4.946 8.3285 3.8946 11.4055
BT 271 CTRP2 4.9469 11.6626 2.2754 17.8828
BT 444 CTRP2 4.9661 8.6838 3.7454 11.965
BT 422 CTRP2 5.0372 7.863 4.2023 9.9347
BT 440 CTRP2 5.0378 7.7664 4.2477 9.7495
BT 286 CTRP2 5.0899 10.8069 2.8274 15.4065
BT 498 CTRP2 5.4434 6.9839 5.0126 5.6562
BT 340 CTRP2 5.7617 9.3129 4.169 8.445
BT 482 CTRP2 5.842 10.3087 3.7413 10.0691
BT 328 CTRP2 7.1718 12.9824 3.4642 8.8145
⏷ Show the Full List of 86 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 60 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Daoy GDSC1 -2.9796 -1.389 -2.9797 88.3481
D283 Med GDSC1; CTRP2 -2.2609 -0.8999 -2.2609 55.3311
GaMG GDSC1 -1.9646 0.0886 -1.9669 76.8641
GB-1 GDSC1 -1.9594 -0.0604 -1.9606 77.1378
GI-1 GDSC1 -1.7698 -0.4024 -1.7699 75.7928
MOG-G-CCM GDSC1 -1.6404 1.6828 -1.6979 70.5236
SF268 GDSC1; CTRP2 -1.5705 0.4461 -1.5709 50.7308
MOG-G-UVW GDSC1 -1.3815 0.7114 -1.3863 70.3
AM-38 GDSC1 -1.2289 1.9607 -1.291 66.6966
D-566MG GDSC1 -0.9252 1.1446 -0.9323 65.0164
D-423MG GDSC1 -0.8818 1.9443 -0.926 63.5936
KINGS-1 GDSC1 -0.7684 0.8686 -0.77 63.454
D-542MG GDSC1 -0.6021 1.9134 -0.6328 60.8007
SF126 GDSC1 -0.4899 1.1606 -0.4924 60.0295
D-247MG GDSC1 -0.3563 1.1226 -0.3576 58.4253
M059J GDSC1 -0.2245 2.3978 -0.2762 56.3529
U-251MG GDSC1; CTRP2 -0.2056 0.6937 -0.2056 41.6382
SF295 GDSC1 -0.1174 1.0728 -0.1177 55.4842
KNS-81-FD GDSC1 -0.0943 2.1102 -0.1186 55.0084
8-MG-BA GDSC1; CTRP2 -0.0523 2.4136 -0.0621 40.6469
KS-1 [Human Krukenberg tumour] GDSC1 0.2625 3.4646 0.0929 50.6532
A-172 GDSC1; CTRP2 0.2834 1.6181 0.2833 38.3811
D-502MG GDSC1 0.477 2.2546 0.4631 48.0897
M059K CTRP2 0.5299 3.0237 0.5124 36.7952
SW1783 GDSC1; CTRP2 0.6553 2.8133 0.6472 35.9293
42-MG-BA GDSC1; CTRP2 0.7262 4.0602 0.6376 35.7129
LN-229 GDSC1 0.7796 3.6149 0.6236 44.7814
CAS-1 GDSC1 0.9033 2.9792 0.8539 42.9538
KALS-1 GDSC1 0.9721 4.6832 0.5614 43.2909
SK-MG-1 GDSC1 0.9808 3.5097 0.861 42.2832
NMC-G1 GDSC1 0.9856 3.2212 0.9117 42.0454
YH-13 GDSC1; CTRP2 0.9904 3.5473 0.9605 33.7693
Onda 10 GDSC1 0.996 2.6551 0.9778 41.6694
LN-405 GDSC1 1.0308 2.7967 1.0044 41.2767
Becker GDSC1; CTRP2 1.071 3.5253 1.0452 33.219
DBTRG-05MG GDSC1 1.2345 4.8583 0.7922 40.5194
LN-18 GDSC1 1.2419 2.2603 1.2407 38.5078
DK-MG GDSC1; CTRP2 1.2487 3.8755 1.2062 32.0911
D-392MG GDSC1 1.4457 3.8691 1.294 36.8016
Hs 683 GDSC1; CTRP2 1.4846 3.9842 1.444 30.5135
TM-31 CTRP2 1.5924 3.5537 1.5803 29.6999
D-263MG GDSC1 1.6205 2.3859 1.6202 33.7692
T98G GDSC1; CTRP2 1.793 3.4328 1.788 28.34
KG-1-C CTRP2 1.8008 4.2499 1.7523 28.4342
SF539 GDSC1; CTRP2 1.863 6.6819 1.2923 29.7768
U-118MG GDSC1; CTRP2 1.8665 4.0643 1.8363 27.9351
PFSK-1 GDSC1 1.9104 3.0465 1.9007 30.2046
YKG-1 GDSC1; CTRP2 2.0078 4.332 1.9622 27.0458
U-87MG ATCC GDSC1 2.1712 3.3595 2.1513 27.0097
GMS-10 CTRP2 2.467 4.0128 2.4583 23.862
GOS-3 CTRP2 2.6359 6.851 2.0768 24.6752
Onda 11 GDSC1 2.8509 5.6997 2.207 22.8021
KNS-42 GDSC1; CTRP2 2.9807 5.2332 2.8823 20.7462
SW1088 GDSC1 3.0813 5.6503 2.4663 19.8068
SNB-75 GDSC1; CTRP2 3.1788 8.3713 2.0757 23.0983
CCF-STTG1 CTRP2 3.683 6.0739 3.4592 16.5156
ONS-76 GDSC1 5.9191 12.1623 1.6399 14.8291
D-336MG GDSC1 5.9376 10.5669 2.4216 9.7739
H4 GDSC1 6.2586 14.4226 0.7805 18.552
LNZTA3WT4 GDSC1 6.4125 8.1066 3.7623 0.62
⏷ Show the Full List of 60 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1 -0.6155 2.7157 -0.728 60.0733
TGBC24TKB GDSC1 -0.1029 2.2669 -0.138 55.0501
TGBC1TKB GDSC1 0.3717 2.3299 0.3508 49.3912
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RL95-2 GDSC1 -1.3718 -0.0819 -1.3719 71.0295
ESS-1 GDSC1; CTRP2 -0.7604 1.0174 -0.7607 45.3352
MFE-280 GDSC1 -0.2931 3.1565 -0.451 56.5492
JHUEM-3 CTRP2 0.4033 3.9016 0.3137 37.8551
KLE GDSC1 0.4224 3.8047 0.1955 48.9179
HEC-1-A CTRP2 0.9372 3.1824 0.9235 34.0702
JHUEM-7 CTRP2 1.0007 4.0123 0.9332 33.8231
EN GDSC1; CTRP2 1.1888 5.1019 0.9698 33.061
MFE-319 GDSC1; CTRP2 1.3295 2.9332 1.3272 31.4187
AN3-CA GDSC1; CTRP2 1.4688 4.5104 1.3708 30.8108
JHUEM-1 CTRP2 1.5741 3.4923 1.5638 29.8162
MFE-296 GDSC1; CTRP2 2.5728 6.4208 2.1467 24.6176
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KTCTL-21 GDSC1 -2.4703 0.9387 -2.5088 77.8172
KTCTL-1M GDSC1 -1.4872 1.9385 -1.5605 68.8023
NCC021 GDSC1 -1.3421 1.1682 -1.3581 69.1626
KTCTL-140 GDSC1 -1.3022 1.2533 -1.3205 68.6439
769-P GDSC1 -1.1038 0.9496 -1.1094 67.1362
RXF 393L GDSC1 -1.0175 1.3568 -1.0328 65.7337
LB1047-RCC GDSC1 -0.9782 0.665 -0.9795 66.0105
Caki-1 GDSC1; CTRP2 -0.5201 2.1802 -0.5318 43.7642
BB65-RCC GDSC1 -0.3986 1.4521 -0.4047 58.8324
VMRC-RCZ GDSC1; CTRP2 -0.1895 1.3193 -0.1897 41.5318
KTCTL-195 GDSC1 -0.1816 2.1321 -0.2105 56.0089
KTCTL-26A GDSC1 -0.1038 1.4519 -0.1065 55.2823
CAL-54 GDSC1; CTRP2 0.2093 3.0051 0.1836 38.9543
UO-31 GDSC1; CTRP2 0.495 3.2352 0.4662 37.0634
OS-RC-2 GDSC1 0.6113 4.0138 0.3522 46.893
ACHN GDSC1; CTRP2 0.7948 3.0095 0.7838 35.01
VMRC-RCW GDSC1 1.2113 3.396 1.1278 39.3248
LB2241-RCC GDSC1 1.4611 3.0695 1.4323 35.9342
BFTC-909 GDSC1 1.4896 2.6865 1.4837 35.4405
KMRC-3 CTRP2 1.7268 7.0386 1.0278 31.0685
LB996-RCC GDSC1 2.0937 3.4788 2.058 28.0781
TUHR14TKB CTRP2 2.1299 4.2854 2.0942 26.1988
KMRC-20 GDSC1 2.1398 4.1772 1.9784 28.3073
KMRC-1 GDSC1; CTRP2 2.2113 4.487 2.1614 25.7048
Caki-2 CTRP2 2.3481 4.9608 2.2463 24.9709
786-O GDSC1; CTRP2 2.405 4.1242 2.3902 24.2958
SN12C GDSC1 2.4115 4.3376 2.2327 25.0444
A-498 GDSC1; CTRP2 2.5308 3.8092 2.528 23.4174
SW156 GDSC1 2.9401 6.675 1.8606 24.645
RCC10RGB GDSC1; CTRP2 3.6136 5.872 3.4366 16.8093
KMRC-2 CTRP2 3.836 10.0425 2.0005 21.6016
SW13 GDSC1 4.5358 7.0195 3.147 8.5102
TK-10 GDSC1 5.8573 9.1827 3.0207 5.8185
KTCTL-13 GDSC1 6.6055 12.4035 1.9889 10.9242
HA7-RCC GDSC1 6.7304 8.9614 3.5719 1.1315
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 51 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LS411N GDSC1 -2.6116 -0.4076 -2.6136 82.9618
SNU-61 GDSC1 -2.1396 -0.0346 -2.1419 78.5928
HCT 116 GDSC1 -1.9976 0.1586 -2.0008 76.9793
SW837 GDSC1 -1.7399 -0.1526 -1.7402 75.1776
SNU-175 GDSC1 -1.6965 -0.0329 -1.697 74.5663
GP2d CTRP2 -1.5353 0.5006 -1.5359 50.497
SW620 GDSC1 -1.3528 0.1842 -1.3532 70.6269
CCK-81 GDSC1 -1.26 -0.0736 -1.2601 69.6984
SNU-C2B GDSC1 -1.1049 1.9309 -1.1583 65.6791
SW948 GDSC1; CTRP2 -1.0859 0.4843 -1.0859 47.503
RKO GDSC1 -1.0587 1.7251 -1.0944 65.5961
HT-29 GDSC1 -0.8296 1.0196 -0.8332 64.066
MDST8 GDSC1 -0.8164 0.1281 -0.8164 64.2219
COLO205 GDSC1 -0.7286 1.2182 -0.7345 62.7788
COLO 320HSR GDSC1 -0.519 7.671 -2.1423 55.1382
GP5d GDSC1 -0.4582 1.0331 -0.4593 59.6849
HT115 GDSC1 -0.3567 1.0372 -0.3575 58.4461
SW48 GDSC1 -0.3159 1.938 -0.338 57.637
KM12 GDSC1 -0.2468 5.1086 -0.8991 54.7897
LS1034 GDSC1; CTRP2 -0.2459 1.5017 -0.2465 41.9086
COLO 320 CTRP2 -0.1808 3.8714 -0.3029 41.7821
SNU-C1 GDSC1; CTRP2 -0.0932 2.1549 -0.0983 40.9054
SW626 GDSC1 -0.0774 0.7916 -0.0774 54.9905
SNU-407 GDSC1 -0.0741 4.9365 -0.6564 53.4849
LS123 GDSC1 -0.021 1.752 -0.0283 54.2244
RCM-1 [Human ESC] GDSC1; CTRP2 0.0157 1.8045 0.0147 40.1673
C2BBe1 GDSC1; CTRP2 0.0201 2.5163 0.0089 40.1693
NCI-H747 GDSC1; CTRP2 0.0513 2.4017 0.0434 39.9518
LS180 GDSC1 0.1928 3.1906 0.0665 51.4502
SNU-C5 GDSC1 0.2003 3.4198 0.0342 51.334
CaR-1 GDSC1 0.2341 2.9219 0.1505 51.0174
HCC-56 CTRP2 0.271 2.2305 0.2682 38.4722
SW1417 GDSC1; CTRP2 0.2853 2.0746 0.2839 38.3726
CW-2 GDSC1 0.3667 6.2052 -0.6232 49.6434
T84 GDSC1; CTRP2 0.4172 3.2328 0.3859 37.5884
SW1116 GDSC1 0.5153 4.3383 0.1631 48.0248
HT-55 GDSC1 0.6582 1.6872 0.6578 45.7985
CL-11 GDSC1 0.8046 5.882 -0.0324 45.7899
LoVo GDSC1 0.8688 3.9713 0.6431 43.9401
LS513 GDSC1 0.9065 4.8789 0.4288 44.153
HCC2998 GDSC1 0.9757 2.5282 0.9635 41.8922
SNU-503 CTRP2 1.0162 5.4774 0.7008 34.4913
HCT 8 CTRP2 1.0889 3.0783 1.0813 33.0394
COLO 678 GDSC1; CTRP2 1.1824 4.6894 1.0374 32.8667
NCI-H716 GDSC1; CTRP2 1.2375 4.5917 1.1118 32.439
HCT 15 GDSC1; CTRP2 1.3181 3.5183 1.3004 31.5464
SNU-1033 CTRP2 1.4593 2.8289 1.4585 30.5491
SW1463 GDSC1 2.1068 3.6781 2.045 28.0811
SNU-C4 CTRP2 3.1021 6.0191 2.8403 20.5159
SNU-1040 GDSC1 3.2041 7.9656 1.5014 25.5456
SNU-81 GDSC1 5.8842 8.4245 3.3798 3.3239
⏷ Show the Full List of 51 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1 -0.8749 3.608 -1.1717 61.1286
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-1 GDSC1; CTRP2 -3.594 -3.005 -3.594 64.2122
HLE GDSC1 -1.0747 1.1118 -1.0835 66.6355
SNU-475 GDSC1; CTRP2 -0.6991 1.7903 -0.705 44.9409
SNU-423 GDSC1; CTRP2 -0.6967 1.9781 -0.7063 44.9332
JHH-4 GDSC1; CTRP2 -0.5867 1.5144 -0.5885 44.1823
JHH-2 GDSC1; CTRP2 -0.5192 1.5233 -0.5208 43.7321
SNU-398 GDSC1 -0.477 3.4546 -0.7066 58.0107
Hep 3B2.1-7 GDSC1 -0.4681 1.1449 -0.4702 59.7737
Huh-7 GDSC1 -0.2515 1.102 -0.2523 57.1433
SNU-387 GDSC1; CTRP2 0.5054 4.2883 0.3727 37.3051
JHH-7 GDSC1 0.8139 2.2519 0.8078 43.8798
PLC/PRF/5 CTRP2 1.3233 2.6573 1.3228 31.4541
JHH-5 CTRP2 1.4766 4.0368 1.4313 30.5828
HLF CTRP2 1.9509 3.3786 1.9486 27.2791
SNU-449 GDSC1; CTRP2 1.951 4.8104 1.8435 27.6344
HuH-1 GDSC1; CTRP2 2.0109 3.9959 1.9903 26.9405
SK-HEP-1 GDSC1; CTRP2 2.125 3.3189 2.1242 26.1144
Hep-G2/C3A GDSC1 2.3296 3.1965 2.3245 24.9362
JHH-6 GDSC1; CTRP2 5.0281 8.9822 3.6614 12.1626
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 193 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2731 GDSC1 -4.6411 0.0761 -4.7061 87.1576
Lu-135 GDSC1 -3.7994 -0.6455 -3.8094 88.368
COR-L303 GDSC1 -3.5699 -1.8224 -3.57 92.4106
NCI-H2227 GDSC1 -3.3661 -1.1793 -3.367 89.2802
NCI-H847 GDSC1 -3.1867 -2.2605 -3.1867 92.4283
NCI-H211 GDSC1 -3.1555 -1.1377 -3.156 88.3219
IST-SL1 GDSC1 -3.1065 -1.5567 -3.1066 89.6118
SBC-3 GDSC1 -2.9893 1.2656 -3.0761 79.0847
COR-L321 GDSC1 -2.9805 -1.715 -2.9805 89.4035
NCI-H1755 GDSC1 -2.7848 0.9277 -2.8344 79.3604
LC-2/ad GDSC1 -2.5941 -0.4308 -2.5959 82.9282
Ms-1 GDSC1 -2.4987 -0.4437 -2.4999 82.3486
NCI-H810 GDSC1; CTRP2 -2.3215 -0.0989 -2.322 55.727
NCI-H292 GDSC1 -2.2557 1.6519 -2.3416 74.5129
HCC33 GDSC1 -2.165 -0.3148 -2.1657 79.4762
UMC-11 GDSC1 -2.1637 -1.2483 -2.1637 80.9352
NCI-H146 CTRP2 -2.1394 -1.0144 -2.1394 54.5219
NCI-H748 GDSC1 -2.0139 -0.263 -2.0145 78.0382
NCI-H510A GDSC1 -2.0009 0.0534 -2.0031 77.251
NCI-H2135 GDSC1 -1.9983 -0.0966 -1.9994 77.5583
SBC-1 GDSC1 -1.9633 -0.0873 -1.9644 77.2279
Lu-139 GDSC1 -1.888 -0.2515 -1.8884 76.8205
NCI-H196 GDSC1 -1.8842 -0.2932 -1.8845 76.8491
EPLC-272H GDSC1 -1.8494 1.7853 -1.9269 71.718
COR-L279 CTRP2 -1.8357 0.0337 -1.8359 52.4976
HCC44 GDSC1 -1.7782 0.867 -1.7933 73.5227
NCI-H446 GDSC1 -1.694 0.2025 -1.6956 74.1767
NCI-H1105 CTRP2 -1.687 -0.072 -1.687 51.5075
NCI-H64 GDSC1 -1.6032 -0.3881 -1.6032 73.9039
NCI-H1688 GDSC1 -1.5891 0.2207 -1.5904 73.1113
NCI-H526 GDSC1 -1.5672 0.4964 -1.5708 72.4576
NCI-H1581 GDSC1 -1.5512 -0.6674 -1.5512 73.3891
NCI-H358 GDSC1 -1.4341 1.5738 -1.4744 69.168
HCC78 GDSC1 -1.4133 0.8521 -1.4212 70.3813
NCI-H2171 GDSC1; CTRP2 -1.4018 -0.3936 -1.4018 49.6075
LK-2 GDSC1 -1.338 -0.6173 -1.338 70.7453
Calu-6 GDSC1 -1.3304 0.898 -1.3381 69.5079
NCI-H1341 CTRP2 -1.3187 -0.0052 -1.3187 49.0542
DMS 273 GDSC1; CTRP2 -1.3073 2.187 -1.3382 48.996
COR-L51 CTRP2 -1.2723 0.3032 -1.2723 48.7449
NCI-H1694 GDSC1; CTRP2 -1.266 0.4569 -1.2661 48.703
NCI-H1648 GDSC1 -1.2618 1.8311 -1.3141 67.2191
PC-14 GDSC1 -1.2602 1.1582 -1.2739 68.412
SBC-5 GDSC1 -1.2437 -0.6963 -1.2437 69.5698
Lu-134-A GDSC1 -1.2221 1.1611 -1.2351 68.0413
VMRC-LCD CTRP2 -1.1789 1.6235 -1.1877 48.1332
NCI-H2081 GDSC1; CTRP2 -1.1335 1.2673 -1.1366 47.8247
NCI-H1836 GDSC1 -1.0598 1.5915 -1.0874 65.814
NCI-H226 GDSC1 -1.054 0.0389 -1.054 67.1671
NCI-H187 GDSC1 -1.0452 0.7268 -1.0473 66.7244
DV-90 CTRP2 -1.0441 1.5652 -1.0502 47.2349
COR-L88 GDSC1; CTRP2 -1.035 1.0112 -1.036 47.166
NCI-H661 GDSC1 -1.032 0.1737 -1.0321 66.8695
NCI-H3122 GDSC1 -1.0273 2.4974 -1.1377 64.0522
SHP-77 GDSC1 -0.9605 2.4079 -1.0553 63.6253
Lu-165 GDSC1 -0.9338 1.4316 -0.95 64.7855
NCI-H23 GDSC1; CTRP2 -0.8432 1.6699 -0.8487 45.898
NCI-H345 GDSC1 -0.8163 0.9485 -0.8189 63.9636
NCI-H1975 GDSC1 -0.8143 2.8884 -0.9671 61.6434
LCLC-97TM1 GDSC1 -0.7803 1.3972 -0.7917 63.2011
CPC-N GDSC1 -0.7361 0.354 -0.7361 63.2087
NCI-H1155 GDSC1 -0.7167 0.5708 -0.7169 62.9378
NCI-H1876 GDSC1 -0.6651 1.7783 -0.6899 61.5982
EMC-BAC-2 GDSC1 -0.6327 1.3475 -0.64 61.601
LK2 CTRP2 -0.5649 0.4159 -0.5649 44.0324
NCI-H1915 GDSC1; CTRP2 -0.5294 2.4805 -0.5518 43.8509
NCI-H520 GDSC1; CTRP2 -0.5149 2.6333 -0.544 43.7704
NCI-H1944 GDSC1; CTRP2 -0.5125 1.7088 -0.5156 43.6917
DMS 454 CTRP2 -0.4806 2.9077 -0.5248 43.5768
NCI-H1092 GDSC1; CTRP2 -0.4735 2.2342 -0.4859 43.4562
NCI-H522 GDSC1; CTRP2 -0.4248 3.0889 -0.4799 43.2329
COR-L23 GDSC1 -0.3452 3.7739 -0.633 56.5473
NCI-H1734 GDSC1 -0.2922 1.9848 -0.3161 57.342
LC-1/sq GDSC1 -0.2861 2.9411 -0.4083 56.6413
NCI-H2595 GDSC1 -0.28 1.6258 -0.2886 57.3646
COLO 668 GDSC1; CTRP2 -0.2714 3.3703 -0.3432 42.2606
SW1271 GDSC1 -0.2706 2.0399 -0.2969 57.0672
NCI-H1623 GDSC1; CTRP2 -0.1905 2.7113 -0.2138 41.6044
NCI-H2444 GDSC1 -0.1791 5.4912 -0.9527 54.0621
NCI-H2110 GDSC1; CTRP2 -0.1305 2.8059 -0.1565 41.213
LCLC-103H GDSC1 -0.1195 1.4532 -0.1224 55.4744
NCI-H2029 GDSC1; CTRP2 -0.1115 2.6386 -0.1296 41.065
NCI-H2803 GDSC1 -0.0802 1.613 -0.0852 54.968
DMS 79 GDSC1 -0.0422 1.6879 -0.0484 54.4938
NCI-H2087 GDSC1 -0.0409 1.9855 -0.057 54.4152
NCI-H1770 GDSC1 -0.029 1.0726 -0.0292 54.3832
NCI-H2373 GDSC1 -0.0253 1.5807 -0.0291 54.3028
NCI-H2722 GDSC1 -0.0194 2.1075 -0.041 54.1292
EBC-1 GDSC1 0.0058 3.756 -0.2468 53.2561
LXF 289 GDSC1 0.041 2.106 0.0214 53.4125
NCI-H1666 GDSC1 0.0846 2.5289 0.0363 52.8074
NCI-H596 GDSC1 0.113 3.6046 -0.0973 52.2203
SK-MES-1 GDSC1; CTRP2 0.1359 3.5447 0.0686 39.5607
NCI-H1436 GDSC1 0.1381 1.9422 0.1281 52.2625
NCI-H1437 GDSC1 0.1813 4.0001 -0.1132 51.4378
ABC-1 GDSC1 0.2066 6.1454 -0.772 50.907
NCI-H2196 GDSC1; CTRP2 0.2071 3.1957 0.1703 39.0016
NCI-H650 GDSC1 0.2178 3.1937 0.0929 51.1722
NCI-H1651 GDSC1; CTRP2 0.2319 3.785 0.1454 38.9792
LOU-NH91 GDSC1 0.2581 1.2234 0.2581 50.7972
NCI-H2347 GDSC1 0.2667 3.7322 0.0423 50.5891
NCI-H2141 GDSC1; CTRP2 0.271 3.4945 0.2147 38.6346
CAL-12T GDSC1 0.2803 7.0066 -1.0298 50.2985
HARA [Human squamous cell lung carcinoma] GDSC1 0.2931 3.3322 0.1504 50.3226
LUDLU-1 CTRP2 0.2991 3.0479 0.2741 38.3546
NCI-H1048 GDSC1 0.303 2.5866 0.2604 50.2272
NCI-H2804 GDSC1 0.3232 3.0288 0.231 49.9848
NCI-H1339 CTRP2 0.3442 3.1118 0.3172 38.0606
COR-L95 GDSC1; CTRP2 0.3459 2.7054 0.3353 37.9986
HOP-62 GDSC1; CTRP2 0.3475 4.0442 0.2373 38.2824
LC-1/sq-SF CTRP2 0.3717 4.1828 0.2446 38.1705
RERF-LC-MS GDSC1; CTRP2 0.4319 3.0601 0.4102 37.4608
NCI-H2030 GDSC1 0.4932 2.6932 0.4504 47.9373
NCI-H2170 GDSC1; CTRP2 0.4949 2.6863 0.4872 36.9967
NCI-H2869 GDSC1 0.5073 2.8577 0.4485 47.791
HCC827 GDSC1 0.5206 2.2791 0.5069 47.55
Lu-65 GDSC1; CTRP2 0.5773 4.492 0.4189 36.906
T3M-10 CTRP2 0.5799 3.1901 0.5563 36.4816
DMS 53 GDSC1; CTRP2 0.5816 3.2628 0.5541 36.4829
NCI-H322M GDSC1 0.5982 3.8592 0.3744 46.9861
COR-L105 GDSC1; CTRP2 0.6836 4.6338 0.51 36.2509
NCI-H838 GDSC1; CTRP2 0.725 3.1532 0.7072 35.4972
NCI-H1573 GDSC1 0.7779 2.773 0.742 44.4437
NCI-H1693 GDSC1; CTRP2 0.8563 5.4058 0.5432 35.5267
RERF-LC-Sq1 GDSC1 0.8933 2.5871 0.8755 42.9441
PaCa-3 GDSC1 0.9624 7.229 -0.4062 45.1681
BEN GDSC1 0.9956 4.5906 0.615 42.9527
NCI-H2172 GDSC1 1.0718 3.8281 0.8965 41.4087
NCI-H841 GDSC1; CTRP2 1.0847 2.4866 1.0842 33.044
NCI-H647 GDSC1; CTRP2 1.1419 3.1477 1.1335 32.6891
EMC-BAC-1 GDSC1 1.1773 9.4402 -1.17 44.8127
NCI-H2795 GDSC1 1.2059 2.4941 1.2001 38.9848
ChaGo-K-1 GDSC1; CTRP2 1.2803 4.8536 1.1152 32.283
NCI-H2369 GDSC1 1.3157 2.7775 1.3014 37.6632
IA-LM GDSC1; CTRP2 1.3967 4.0374 1.3475 31.1277
SW1573 GDSC1 1.4754 3.2701 1.4269 35.8707
NCI-H322 CTRP2 1.4766 4.307 1.4044 30.6726
Lu-99A GDSC1 1.5001 5.8038 0.7408 38.7938
NCI-H1869 GDSC1; CTRP2 1.5739 3.8346 1.5475 29.8713
SK-LU-1 GDSC1 1.5969 3.4656 1.5306 34.4638
NCI-H1792 GDSC1 1.5978 3.2223 1.5616 34.2735
HCC4006 CTRP2 1.6343 3.2611 1.6304 29.3937
HOP-92 GDSC1; CTRP2 1.6402 4.2695 1.5814 29.5385
A-549 GDSC1 1.6523 3.0507 1.6334 33.4877
NCI-H2405 GDSC1 1.7118 5.1718 1.2032 35.4294
NCI-H1568 GDSC1; CTRP2 1.7678 3.2363 1.7656 28.4985
NCI-H2085 GDSC1 1.7681 7.0737 0.4945 37.9112
DMS 114 GDSC1; CTRP2 1.7849 5.0762 1.6199 28.9347
NCI-H2461 GDSC1 1.8227 5.9873 1.0104 35.5904
NCI-H69 GDSC1 1.8414 3.0966 1.8268 31.098
NCI-H1781 GDSC1 1.9213 5.0321 1.4787 32.6532
HCC2935 CTRP2 2.099 3.8229 2.0888 26.3188
NCI-H2023 GDSC1 2.1354 4.6752 1.8306 29.2678
NCI-H727 GDSC1 2.1588 7.7688 0.5782 35.3332
Calu-3 GDSC1 2.3025 6.0766 1.4768 30.3678
NCI-H1993 GDSC1 2.3454 6.0619 1.5277 29.8369
HCC1438 CTRP2 2.3762 5.1131 2.2516 24.8624
NCI-H1395 CTRP2 2.4073 6.0121 2.0839 25.3502
NCI-H3255 GDSC1 2.4086 5.0246 2.0072 26.5468
NCI-H2591 GDSC1 2.4293 7.2123 1.1039 31.5862
NCI-H2122 GDSC1 2.6138 6.2091 1.7416 27.0881
NCI-H2228 GDSC1 2.6221 7.0848 1.355 29.2663
RERF-LC-Ad2 CTRP2 2.7153 5.6577 2.509 22.8911
NCI-H1563 GDSC1; CTRP2 2.7186 6.214 2.3672 23.3852
NCI-H1304 GDSC1 2.7234 3.5183 2.7148 20.0361
NCI-H1650 GDSC1 2.7573 5.7485 2.0891 24.0918
NCI-H1299 GDSC1 2.8812 6.1414 2.0446 23.7434
NCI-H1793 GDSC1; CTRP2 2.8911 5.5684 2.7205 21.5953
NCI-H2342 GDSC1; CTRP2 2.9651 5.8368 2.7382 21.3025
NCI-H1703 GDSC1; CTRP2 3.068 5.1953 2.9824 20.1204
A-427 GDSC1 3.0798 8.4592 1.1448 28.0728
NCI-H441 GDSC1 3.0994 6.5767 2.064 22.5219
HCC15 GDSC1 3.4003 7.2383 2.039 21.2695
NCI-H82 GDSC1 3.4106 17.8525 -3.2171 38.7897
KNS-62 CTRP2 3.4328 7.1027 2.8486 19.5075
RERF-LC-KJ GDSC1 3.4449 6.9046 2.2427 19.6651
NCI-H2818 GDSC1 3.4698 9.4023 1.0408 26.8283
Calu-1 CTRP2 3.8252 7.1816 3.239 16.9211
EKVX GDSC1; CTRP2 3.8739 9.4152 2.3282 20.2828
LB647-SCLC GDSC1 3.9177 13.0538 -0.3852 30.8582
NCI-H460 GDSC1 4.1827 6.4523 3.1386 9.8427
NCI-H1963 GDSC1 4.6354 6.8299 3.3187 6.844
NCI-H2009 GDSC1 5.0152 8.6908 2.6849 10.4911
NCI-H1355 GDSC1 5.2861 9.7437 2.3666 11.957
NCI-H1838 GDSC1 5.4004 10.6518 2.0046 14.0596
NCI-H2291 GDSC1 5.9283 8.7182 3.2742 3.9373
NCI-H720 GDSC1 5.9901 11.487 2.0163 12.3076
NCI-H513 GDSC1 5.9933 9.6137 2.9052 6.3151
NCI-H1435 GDSC1 6.4493 8.0829 3.7856 0.5169
NCI-H524 GDSC1 6.5591 8.4952 3.677 0.837
NCI-H209 GDSC1 6.5881 8.6918 3.6144 1.0725
IST-SL2 GDSC1 7.3538 9.6713 3.5615 0.7236
Hs 888.Lu CTRP2 2.3006 6.3172 1.881 26.3938
⏷ Show the Full List of 193 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1 -0.2785 3.4083 -0.482 56.2181
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
P-STS CTRP2 -1.5982 -0.2202 -1.5982 50.916
H-STS CTRP2 -0.9374 0.4031 -0.9374 46.514
SYO-1 CTRP2 0.3816 3.1359 0.3545 37.8121
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 0.8286 4.1631 0.734 35.0527
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 1.3925 4.0374 1.343 31.1567
Aska-SS CTRP2 1.7752 3.4193 1.7702 28.4588
EW-8 GDSC1 -2.001 -0.3514 -2.0013 78.0834
Hs 633.T GDSC1 -1.5304 -0.2496 -1.5305 72.974
SW872 GDSC1 -0.8208 0.3139 -0.8208 64.2587
Rh30 GDSC1 -0.3512 1.2248 -0.3534 58.3415
KYM-1 GDSC1; CTRP2 -0.087 2.0649 -0.0908 40.8601
G-401 GDSC1; CTRP2 -0.0333 2.6281 -0.0492 40.5385
RKN GDSC1 0.1772 2.6422 0.1228 51.7093
RD GDSC1; CTRP2 0.3211 2.7752 0.3079 38.172
HT-1080 GDSC1; CTRP2 0.5121 3.2343 0.4839 36.9474
MFH-ino GDSC1 0.518 2.5901 0.4852 47.6193
A-204 GDSC1; CTRP2 0.6589 5.2243 0.3689 36.7447
Rh41 GDSC1 0.7031 3.788 0.5046 45.7618
TE 617.T CTRP2 0.7842 3.627 0.7406 35.186
TE 441.T CTRP2 1.003 3.5391 0.9741 33.6821
G-402 GDSC1; CTRP2 1.6432 4.7613 1.521 29.7319
SK-LMS-1 GDSC1; CTRP2 1.6632 3.4734 1.6552 29.2148
VA-ES-BJ GDSC1 1.6825 3.0002 1.668 33.0833
MES-SA GDSC1; CTRP2 1.7394 3.174 1.7376 28.6866
GCT GDSC1; CTRP2 1.9453 4.5462 1.8733 27.5515
SW982 GDSC1; CTRP2 2.1831 3.5911 2.18 25.735
TTC-709 CTRP2 2.2189 5.1599 2.0735 25.9814
Tm87-16 CTRP2 2.4976 5.4807 2.3117 24.2679
SK-UT-1 GDSC1; CTRP2 2.6158 4.9192 2.539 23.1022
BT-12 CTRP2 2.6734 4.9599 2.5949 22.7242
Hs 729.T CTRP2 3.1652 8.7596 1.897 23.7827
BT-16 CTRP2 3.6695 7.3054 3.025 18.1711
SW684 GDSC1 4.8542 6.5758 3.6018 4.016
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 1.8772 5.0433 1.7257 28.2752
OVCAR-8 GDSC1 -2.2235 -0.0473 -2.2262 79.2691
ES-2 GDSC1 -1.8967 1.4116 -1.9443 73.0035
SK-OV-3 GDSC1 -1.3038 0.6327 -1.3067 69.619
A2780 GDSC1 -1.1426 0.8089 -1.1464 67.7092
IGROV-1 GDSC1 -0.9113 2.381 -0.9998 63.2323
EFO-27 GDSC1; CTRP2 -0.8288 2.0029 -0.8411 45.8158
TOV-112D GDSC1; CTRP2 -0.8152 2.6462 -0.8552 45.7744
TYK-nu GDSC1 -0.7322 2.9182 -0.8837 60.8879
OVCAR-5 GDSC1; CTRP2 -0.6076 2.7093 -0.644 44.3991
OAW28 GDSC1; CTRP2 -0.549 2.3668 -0.5674 43.9721
RMG-I GDSC1 -0.3656 1.8816 -0.3863 58.2324
OVKATE GDSC1 -0.3264 3.6388 -0.582 56.4863
COV644 CTRP2 -0.0199 4.0639 -0.157 40.7663
Kuramochi GDSC1 0.0326 1.9536 0.0198 53.5412
JHOM-1 CTRP2 0.1259 2.8538 0.105 39.4943
OC 314 GDSC1; CTRP2 0.3665 1.6669 0.3664 37.8273
OVTOKO GDSC1 0.5407 3.6366 0.3603 47.5683
COV434 CTRP2 0.5992 3.3569 0.5668 36.3813
OVISE GDSC1 0.7231 2.3332 0.7124 45.0299
OV-90 GDSC1; CTRP2 1.0979 3.0816 1.0904 32.9792
OAW42 GDSC1; CTRP2 1.724 3.2743 1.7209 28.7933
Caov-3 GDSC1 1.9333 6.0763 1.0906 34.5362
EFO-21 GDSC1; CTRP2 1.9884 5.6549 1.7179 27.9434
TOV-21G GDSC1; CTRP2 1.9972 4.2698 1.9566 27.0994
JHOS-2 GDSC1; CTRP2 2.1516 5.9303 1.8267 27.0496
OV7 CTRP2 2.8411 5.2859 2.7226 21.7457
OVCAR-4 GDSC1 3.1476 6.5065 2.1443 21.7421
OV56 GDSC1; CTRP2 3.1947 5.1388 3.1267 19.2159
FU-OV-1 GDSC1 3.4532 5.9379 2.711 16.2199
COV362 CTRP2 3.9386 6.6807 3.5457 15.4403
DOV13 GDSC1 6.4499 7.9557 3.8317 0.3757
OVK18 GDSC1 6.7318 8.3137 3.8103 0.3112
OVCAR-3 GDSC1 7.143 8.7471 3.8083 0.1895
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MPP 89 GDSC1; CTRP2 -1.1842 3.0444 -1.2722 48.2316
IST-Mes1 GDSC1; CTRP2 0.3386 2.002 0.3378 38.0155
MSTO-211H GDSC1 1.1969 3.2067 1.1387 39.3773
JL-1 CTRP2 2.2658 3.5475 2.264 25.1794
NCI-H28 GDSC1 4.9317 10.4187 1.7656 17.0802
NCI-H2052 GDSC1 5.7865 13.7072 0.7869 19.8536
NCI-H2452 GDSC1 6.3127 8.6221 3.5172 1.8404
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VCaP GDSC1; CTRP2 -2.3642 0.7389 -2.3715 55.9565
22Rv1 GDSC1 -2.2269 1.1932 -2.2725 75.6895
LNCaP clone FGC GDSC1; CTRP2 -1.1161 2.1226 -1.1388 47.7325
NCI-H660 CTRP2 -0.4671 2.8788 -0.5088 43.4821
PC-3 GDSC1 0.202 5.2386 -0.4543 51.0533
DU145 GDSC1; CTRP2 0.6049 3.7124 0.5457 36.4272
PaCa-3 CTRP2 3.4435 9.6111 1.8063 23.3418
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; CTRP2 1.9543 3.7436 1.9437 27.2842
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 -1.6637 -0.3519 -1.6638 74.5697
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RF-48 GDSC1 -2.9964 -0.0622 -3.0075 83.7007
NCI-N87 GDSC1 -1.5745 1.9923 -1.6582 69.327
AGS GDSC1 -0.6028 0.4293 -0.6028 61.5511
23132/87 GDSC1 -0.5306 7.8206 -2.2157 55.1252
NUGC-4 GDSC1 -0.3978 3.6871 -0.6704 57.0885
SNU-1 GDSC1; CTRP2 -0.194 2.3598 -0.2048 41.5932
GCIY GDSC1 -0.1635 4.9182 -0.7481 54.2315
HGC-27 GDSC1; CTRP2 -0.0423 3.8008 -0.1469 40.8335
TGBC11TKB GDSC1 0.0145 1.9003 0.0033 53.7688
SNU-216 CTRP2 0.2905 2.7994 0.2758 38.38
KATO III CTRP2 0.3408 3.332 0.3002 38.1246
KE-39 CTRP2 0.4808 5.1531 0.1908 37.8985
MKN1 GDSC1 0.5385 3.2039 0.4358 47.4865
IM95 GDSC1; CTRP2 0.5523 2.9584 0.5378 36.6364
Fu97 GDSC1 0.5722 1.9018 0.5698 46.8799
NUGC-3 GDSC1 1.0594 4.2415 0.783 41.9168
Hs 746.T GDSC1; CTRP2 1.1366 3.4231 1.1181 32.7579
SH-10-TC CTRP2 1.3621 3.0596 1.3585 31.2064
MKN7 GDSC1; CTRP2 1.433 3.7962 1.4038 30.8193
ECC10 GDSC1 1.4411 12.8878 -2.5478 44.8953
SNU-601 CTRP2 1.6629 4.4481 1.5854 29.4502
MKN74 CTRP2 1.8326 5.5224 1.5792 28.9173
MKN28 GDSC1 1.8732 6.8928 0.6816 36.6078
HuG1-N CTRP2 2.0218 6.0045 1.6652 28.0172
SNU-16 GDSC1; CTRP2 2.0302 3.3872 2.0283 26.7496
LMSU CTRP2 2.1238 5.7439 1.8439 27.0781
NCC-StC-K140 CTRP2 2.3185 5.3426 2.1461 25.4123
SNU-5 GDSC1 2.527 3.5259 2.5098 22.5454
RERF-GC-1B GDSC1 3.6221 12.1926 -0.2108 31.3872
TMK-1 GDSC1 3.8397 9.3579 1.3916 23.3831
MKN45 GDSC1 4.2877 7.0819 2.9133 11.2033
SCH GDSC1 5.2608 8.1801 3.1081 6.6396
OCUM-1 GDSC1 5.7075 8.1019 3.4236 3.3647
HSC-39 GDSC1 5.7988 8.6266 3.2403 4.4246
SNU-685 CTRP2 -0.5124 3.121 -0.5739 43.823
SNG-M GDSC1 3.8298 4.6518 3.669 7.2638
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HTC-C3 GDSC1 -2.3878 1.2536 -2.4446 76.4034
BHT-101 GDSC1 -1.7271 0.9812 -1.7452 72.8484
B-CPAP GDSC1 -1.6976 -0.0368 -1.6981 74.5837
ML-1 [Human leukemia] GDSC1 -1.4424 1.2274 -1.4634 69.947
IHH-4 GDSC1 -0.9104 0.5996 -0.9111 65.2564
8505C GDSC1 -0.5109 1.9104 -0.538 59.8241
CAL-62 GDSC1 -0.3993 2.3376 -0.4543 58.282
WRO GDSC1 0.315 2.7344 0.2586 50.0826
K5 GDSC1 0.4431 1.353 0.443 48.4859
TT2609-C02 GDSC1; CTRP2 0.7142 3.761 0.656 35.6979
FTC-238 CTRP2 0.7219 2.5211 0.7194 35.4675
CGTH-W-1 GDSC1 0.7929 1.8691 0.7921 44.1171
SW579 CTRP2 0.9325 3.5444 0.9007 34.1611
FTC-133 GDSC1; CTRP2 1.6234 3.7694 1.6025 29.5229
KMH-2 GDSC1 3.4054 8.6627 1.3473 25.4942
ASH-3 GDSC1 5.148 9.0125 2.6244 10.5317
TT GDSC1 5.2216 7.8943 3.2185 5.9227
8305C GDSC1 6.3971 7.8107 3.8633 0.3134
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PCI-06A GDSC1 -2.4787 -1.1853 -2.4787 84.1063
SCC-25 GDSC1 -1.9999 1.2781 -2.0424 74.0468
Ca9-22 GDSC1 -1.9166 -0.887 -1.9166 77.8462
NCI-H3118 GDSC1 -1.8567 0.3088 -1.8604 75.454
PE/CA-PJ49 CTRP2 -1.2345 0.8811 -1.2355 48.4942
PCI-04B GDSC1 -1.2267 1.1366 -1.239 68.1246
OSC-19 GDSC1 -1.2192 1.1246 -1.2309 68.0696
JHU-011 GDSC1 -1.1232 0.7054 -1.1256 67.6075
BHY GDSC1 -0.9008 1.8395 -0.9381 63.9223
BICR 78 GDSC1 -0.7863 0.8796 -0.7881 63.6578
SAS GDSC1 -0.7846 0.9132 -0.7867 63.6189
CAL-27 GDSC1; CTRP2 -0.6785 0.4894 -0.6785 44.7889
SCC-9 GDSC1; CTRP2 -0.6547 2.1194 -0.6671 44.66
HO-1-u-1 GDSC1 -0.5879 1.5524 -0.6005 60.952
OSC-20 GDSC1 -0.4447 2.6208 -0.5334 58.5073
KOSC-2 GDSC1 -0.419 2.0489 -0.4515 58.7151
BICR 18 CTRP2 -0.2333 2.9115 -0.2685 41.9197
HO-1-N-1 GDSC1 -0.0896 1.6265 -0.0951 55.0802
SAT [Human HNSCC] GDSC1 0.0225 2.7891 -0.0577 53.4401
SCC-4 GDSC1; CTRP2 0.04 3.0038 0.0089 40.0953
BICR 22 GDSC1; CTRP2 0.1479 3.6599 0.0699 39.5108
PCI-38 GDSC1 0.2403 2.9397 0.1547 50.9451
BB30-HNC GDSC1 0.2907 2.8389 0.2211 50.3661
SKN-3 GDSC1 0.3393 2.5683 0.3001 49.7909
JHU-022 GDSC1 0.5844 5.3224 -0.0681 47.6079
SCC-15 GDSC1 0.6221 3.3969 0.4939 46.5542
PE/CA-PJ41 (clone D2) CTRP2 0.7318 3.7586 0.6748 35.5772
LB771-HNC GDSC1 0.821 3.7291 0.6453 44.3529
BICR 6 CTRP2 1.0035 3.543 0.9743 33.6796
PE/CA-PJ15 GDSC1; CTRP2 1.1424 5.054 0.9289 33.3497
BICR 56 CTRP2 1.1504 3.7898 1.1102 32.7376
HSC-3 GDSC1 1.3642 3.2237 1.3143 37.2606
HSC-2 GDSC1; CTRP2 1.4892 3.1597 1.4854 30.36
HSC-4 GDSC1 1.4952 4.3165 1.2385 36.7351
FaDu GDSC1; CTRP2 1.5298 3.9238 1.4958 30.1905
BICR 31 GDSC1; CTRP2 1.6206 4.7312 1.5014 29.8721
PE/CA-PJ34 (clone C12) CTRP2 1.967 4.3326 1.9193 27.3245
CAL-33 GDSC1; CTRP2 2.1473 3.8054 2.1387 25.9917
BB49-HNC GDSC1 2.3421 5.0999 1.9082 27.5642
Detroit 562 GDSC1 2.824 5.265 2.3593 21.8898
BICR 10 GDSC1 2.9111 4.4732 2.7385 18.7787
KON GDSC1 3.247 4.803 2.9896 15.1902
PCI-30 GDSC1 3.5278 6.8826 2.3317 18.6609
DOK GDSC1 3.8232 4.7532 3.6201 7.6541
BICR 16 CTRP2 3.9379 7.6186 3.1836 16.8218
PCI-15A GDSC1 6.3482 8.2265 3.6903 0.9546
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
5637 GDSC1 -2.3422 -0.9097 -2.3423 82.3145
RT-4 GDSC1 -1.3505 1.1966 -1.3678 69.1882
RT-112 GDSC1 -0.6158 2.0747 -0.6585 60.7844
KU-19-19 GDSC1 -0.3562 0.8519 -0.3564 58.4617
CAL-29 GDSC1 -0.3556 1.3534 -0.3594 58.3584
SCaBER CTRP2 -0.3367 2.0693 -0.3431 42.5305
SW1710 GDSC1 -0.2633 2.4045 -0.3177 56.7736
HT-1197 GDSC1; CTRP2 -0.0813 2.1319 -0.0859 40.8246
UM-UC-3 GDSC1 -0.0728 3.2442 -0.2288 54.2767
BFTC-905 GDSC1 0.0609 2.1729 0.0383 53.1614
TCCSUP GDSC1 0.276 2.2272 0.2575 50.5614
UM-UC-1 CTRP2 0.313 3.9857 0.2079 38.4958
U-BLC1 CTRP2 0.4285 2.4914 0.4237 37.4296
647V GDSC1; CTRP2 0.6239 3.3245 0.5944 36.2075
639V GDSC1 1.4676 3.376 1.4049 36.0492
KMBC-2 CTRP2 1.6948 3.5792 1.6841 29.0136
T24 GDSC1; CTRP2 1.953 5.1608 1.7858 27.8248
J82 GDSC1; CTRP2 2.1945 5.2124 2.0373 26.1846
BC-3C CTRP2 2.293 3.6435 2.2903 25.0013
HT-1376 GDSC1 3.4986 5.8719 2.7866 15.4443
SW780 GDSC1 5.2637 8.2634 3.0701 6.9139
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PA-1 GDSC1 -3.9969 -2.2129 -3.997 94.7636
NEC8 GDSC1 -3.2423 -1.9637 -3.2423 91.7358
BPH-1 GDSC1 -2.3783 0.0647 -2.3836 80.026
C-33 A GDSC1 -2.269 -0.3107 -2.2701 80.3091
SW954 GDSC1 -1.9921 -0.0158 -1.9937 77.3308
OV17R GDSC1 -1.5333 1.7509 -1.5916 69.567
KGN GDSC1 -1.5036 1.7191 -1.5578 69.4096
DSH1 GDSC1 -1.419 1.085 -1.4337 70.0158
Ca Ski GDSC1 -1.3204 1.6155 -1.359 68.1319
HEY GDSC1 -1.1336 1.5574 -1.1617 66.5646
JAR GDSC1 -1.0733 -0.0512 -1.0733 67.4191
NT2-D1 GDSC1 -0.9107 1.5732 -0.9325 64.3731
OVMIU GDSC1 -0.692 1.4396 -0.703 62.1969
LB831-BLC GDSC1 -0.6384 1.7769 -0.6623 61.3154
ME-180 GDSC1 -0.6298 1.0255 -0.6319 61.7468
HT-3 GDSC1 -0.5485 1.8112 -0.5713 60.3142
PEO1 GDSC1 -0.3301 4.4614 -0.7937 55.8845
ACC-OV7 GDSC1 -0.3231 1.9886 -0.3482 57.6893
OVCA420 GDSC1 -0.1025 2.5399 -0.1617 54.9302
SKN GDSC1 -0.0909 1.8851 -0.1041 55.0364
SW962 GDSC1 -0.0013 1.8164 -0.0101 53.9751
UWB1.289 GDSC1 0.0299 4.9696 -0.5537 52.594
OMC-1 [Human cervical carcinoma] GDSC1 0.0367 2.8501 -0.0504 53.2622
HEC-1 GDSC1 0.0901 1.1937 0.0898 52.8964
DoTc2 4510 GDSC1 0.1905 1.8816 0.1834 51.6244
NCC-IT GDSC1 0.425 2.7802 0.3699 48.7719
OVCA433 GDSC1 0.6202 2.0724 0.6153 46.2901
SiSo GDSC1 0.8434 3.2248 0.7592 43.8106
CAL-39 GDSC1 0.8514 6.3739 -0.1723 45.6305
HeLa GDSC1; CTRP2 1.5549 3.3496 1.5482 29.9319
C-4-I GDSC1 2.0677 3.0838 2.0607 28.2212
MS751 GDSC1 2.2493 5.3479 1.7156 29.2958
SW756 GDSC1 2.3378 4.7399 2.0295 26.8085
JEG-3 GDSC1 3.6788 9.9401 0.9604 26.3388
JHOS-3 GDSC1 3.9263 8.1203 2.0837 18.699
SKG-IIIa GDSC1 4.0977 5.4481 3.5626 6.8537
SiHa GDSC1 4.4036 5.2687 3.9148 2.9268
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as PDX-101
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of PDX-101 and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [10]
Coadministration of a Drug Treating the Disease Different from PDX-101 (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of PDX-101 and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [11]
Arn-509 DMT81LZ Moderate Increased metabolism of PDX-101 caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [10]
Gilteritinib DMTI0ZO Moderate Decreased clearance of PDX-101 due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [11]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of PDX-101 and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [12]
Erdafitinib DMI782S Moderate Decreased clearance of PDX-101 due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [13]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of PDX-101 and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [14]
Tucatinib DMBESUA Moderate Decreased metabolism of PDX-101 caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Alpelisib DMEXMYK Moderate Increased metabolism of PDX-101 caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [16]
Regorafenib DMHSY1I Moderate Decreased metabolism of PDX-101 caused by Regorafenib mediated inhibition of UGT. Colorectal cancer [2B91] [17]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of PDX-101 and Cannabidiol. Epileptic encephalopathy [8A62] [10]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of PDX-101 and Brentuximab vedotin. Hodgkin lymphoma [2B30] [18]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of PDX-101 and Mipomersen. Hyper-lipoproteinaemia [5C80] [19]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of PDX-101 and Teriflunomide. Hyper-lipoproteinaemia [5C80] [20]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of PDX-101 and BMS-201038. Hyper-lipoproteinaemia [5C80] [21]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of PDX-101 and Denosumab. Low bone mass disorder [FB83] [22]
PF-06463922 DMKM7EW Moderate Increased metabolism of PDX-101 caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [11]
Capmatinib DMYCXKL Moderate Decreased clearance of PDX-101 due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [23]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of PDX-101 and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [24]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of PDX-101 and Idelalisib. Mature B-cell leukaemia [2A82] [25]
Lasmiditan DMXLVDT Moderate Decreased clearance of PDX-101 due to the transporter inhibition by Lasmiditan. Migraine [8A80] [26]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of PDX-101 and Tecfidera. Multiple sclerosis [8A40] [27]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of PDX-101 and Siponimod. Multiple sclerosis [8A40] [11]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of PDX-101 and Fingolimod. Multiple sclerosis [8A40] [28]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of PDX-101 and Ocrelizumab. Multiple sclerosis [8A40] [29]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of PDX-101 and Ozanimod. Multiple sclerosis [8A40] [10]
Rucaparib DM9PVX8 Moderate Decreased metabolism of PDX-101 caused by Rucaparib mediated inhibition of UGT. Ovarian cancer [2C73] [17]
Abametapir DM2RX0I Moderate Decreased metabolism of PDX-101 caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [30]
Lefamulin DME6G97 Moderate Decreased metabolism of PDX-101 caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [31]
Enzalutamide DMGL19D Moderate Increased metabolism of PDX-101 caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [32]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of PDX-101 and Canakinumab. Rheumatoid arthritis [FA20] [33]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of PDX-101 and Rilonacept. Rheumatoid arthritis [FA20] [33]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of PDX-101 and Golimumab. Rheumatoid arthritis [FA20] [34]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of PDX-101 when combined with Anthrax vaccine. Sepsis [1G40-1G41] [35]
Fostamatinib DM6AUHV Moderate Decreased metabolism of PDX-101 caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [36]
⏷ Show the Full List of 34 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Arginine E00112 6322 Buffering agent; Dispersing agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Belinostat 500mg/vial powder 500mg/vial Powder Intravenous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Belinostat FDA Label
2 A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6 Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013;8(1):e54522.
7 Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. J Clin Pharmacol. 2016 Apr;56(4):461-73.
8 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
9 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
10 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11 Cerner Multum, Inc. "Australian Product Information.".
12 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
13 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
14 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
15 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
16 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
17 Product Information. Beleodaq (belinostat). Spectrum Pharmaceuticals Inc, Irvine, CA.
18 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
19 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
20 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
21 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
22 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
23 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
24 Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
25 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
26 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
27 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
28 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
29 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
30 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
31 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
32 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
33 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
34 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
35 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
36 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.